What is she best known for?
The fields of study she is best known for:
- Immune system
- Cytokine
- Gene
Miyuki Azuma mostly deals with T cell, Immunology, Cell biology, CD8 and Immune system.
Her T cell research incorporates themes from Cytotoxic T cell, Molecular biology and Phosphorylation.
Her research investigates the connection between Immunology and topics such as Blockade that intersect with issues in MHC class I.
Her Cell biology study integrates concerns from other disciplines, such as Peripheral tolerance, Cell, Natural killer cell and Cytokine.
Her CD8 research is multidisciplinary, incorporating elements of Cancer research and Transplantation.
The Immune system study combines topics in areas such as Monoclonal antibody, PTEN and Pathology.
Her most cited work include:
- Expression of Programmed Death 1 Ligands by Murine T Cells and APC (761 citations)
- Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer (724 citations)
- Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase (666 citations)
What are the main themes of her work throughout her whole career to date?
The scientist’s investigation covers issues in Immunology, T cell, Immune system, Cell biology and Cancer research.
The various areas that Miyuki Azuma examines in her Immunology study include Cytotoxic T cell and Blockade.
Her studies deal with areas such as Molecular biology, CD8 and Cytokine as well as T cell.
Her studies in Immune system integrate themes in fields like Inflammation, Internal medicine, Pathogenesis and Pathology.
Her research integrates issues of Peripheral tolerance, Cell, Receptor and T-cell receptor in her study of Cell biology.
Miyuki Azuma has researched Cancer research in several fields, including Leukemia and Immunotherapy.
She most often published in these fields:
- Immunology (54.14%)
- T cell (28.20%)
- Immune system (27.07%)
What were the highlights of her more recent work (between 2013-2021)?
- Immunology (54.14%)
- Immune system (27.07%)
- T cell (28.20%)
In recent papers she was focusing on the following fields of study:
Miyuki Azuma spends much of her time researching Immunology, Immune system, T cell, Cell biology and CD8.
Her study brings together the fields of Downregulation and upregulation and Immunology.
Her Immune system research incorporates elements of Carcinogenesis and Agonist.
Her study in T cell is interdisciplinary in nature, drawing from both Immune checkpoint, Receptor, Blockade, Cytokine and Cytotoxic T cell.
Her Cell biology research is multidisciplinary, relying on both Suppressor, Cell and Interleukin 10.
Her work carried out in the field of CD8 brings together such families of science as Cancer research, Antibody-dependent cell-mediated cytotoxicity and PD-L1.
Between 2013 and 2021, her most popular works were:
- Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. (184 citations)
- An Interleukin-33-Mast Cell-Interleukin-2 Axis Suppresses Papain-Induced Allergic Inflammation By Promoting Regulatory T Cell Numbers (153 citations)
- Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma (47 citations)
In her most recent research, the most cited papers focused on:
- Immune system
- Gene
- Cytokine
Immunology, T cell, Immune system, Blockade and Immune checkpoint are her primary areas of study.
Her Immunology research includes elements of Downregulation and upregulation and CD11c.
She focuses mostly in the field of T cell, narrowing it down to topics relating to Cytokine and, in certain cases, Antibody, Immunohistochemistry and Cancer immunotherapy.
Her Immune system study incorporates themes from Cell signaling, Type 1 diabetes, PTEN and Cell biology.
Her research in Blockade intersects with topics in PD-L1 and Haematopoiesis.
Her Immune checkpoint research is multidisciplinary, incorporating perspectives in Tumor microenvironment, CTLA-4, Cancer research and CD8.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
